Sirtris Pharmaceuticals Sublicenses Portion of Lifespan Technology in Plants to Bayer CropScience AG
March 12 2008 - 8:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT) today announces a
license agreement with Bayer CropScience AG, headquartered in
Monheim, Germany that grants exclusive, worldwide rights in the
field of plants to a certain Sirtris technology that contributes to
cellular life span extension and stress resistance. In return,
Sirtris will receive an initial up-front and future success bound
milestone payments. Further financial terms were not disclosed.
Crop damage from drought, lack of nutrients and other environmental
stresses is of growing worldwide concern. The licensed technology
provides possible new approaches to improving agricultural
productivity. �Sirtris has and continues to build a strong
intellectual property estate around the cellular pathways and
distinct molecules associated with longevity and diseases of
aging,� said Karl Normington, PhD, Senior Director of Intellectual
Property. �Sublicensing portions of our technology to areas that
are outside our principle lines of focus, such as agricultural
productivity, extend the applications of our technology.� �We are
pleased to be working with Bayer CropScience,� said Sirtris
Pharmaceuticals Chief Executive Officer and Vice Chair Christoph
Westphal, MD, PhD. �Because of their focus on improving
agricultural productivity, they are well-positioned to leverage
this important technology for crop yield stability.� Michiel van
Lookeren Campagne, PhD, Head of BioScience Research for Bayer
CropScience welcomes the partnership with Sirtris Pharmaceuticals.
�Global population growth and climate change have put huge pressure
on increasing agricultural productivity under sub-optimal growing
conditions. The integration of Sirtris� proprietary technology into
our seeds and traits R&D pipeline will complement our
activities in obtaining higher yielding crops - especially under
difficult climatic conditions.� About Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our
drug candidates are designed to mimic certain beneficial health
effects of calorie restriction, without requiring a change in
eating habits, by activation of sirtuins, a recently discovered
class of enzymes that the Company believes control the aging
process. The company's headquarters are in Cambridge,
Massachusetts. This and further information is available at:
www.sirtrispharma.com Forward Looking Statement This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, the potential therapeutic effects
of SIRT1 activators; the progress and results of pre-clinical and
clinical studies of SIRT1 activators; the potential of Sirtris'
technology to improve agricultural productivity; the strength of
the Company's intellectual property estate; and the potential of
sirtuin modulators to receive regulatory approval. These
forward-looking statements about future expectations, plans and
prospects of Sirtris Pharmaceuticals involve significant risks,
uncertainties and assumptions, including risks related to the lack
of results that would provide a basis for predicting whether any of
the Company's product candidates will be safe or effective, or
receive regulatory approval, the possibility that results of
pre-clinical studies are not necessarily predictive of clinical
trial results, the Company's potential inability to initiate and
complete pre-clinical studies and clinical trials for its product
candidates, the fact that none of the Company's product candidates
has received regulatory approvals, the potential inability of the
Company to gain market acceptance of the Company's product
candidates, and those other risks factors that can be found in the
Company's filings with the Securities and Exchange Commission.
Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Aug 2023 to Aug 2024